The University of Chicago Header Logo

Connection

Neda Laiteerapong to Hypoglycemic Agents

Back to Details
This is a "connection" page, showing publications Neda Laiteerapong has written about Hypoglycemic Agents.
Neda Laiteerapong
Connection Strength
3.538
Hypoglycemic Agents
  1. Type 2 Diabetes. Ann Intern Med. 2024 06; 177(6):ITC81-ITC96.
    View in: PubMed
    Score: 0.699
  2. Glycemic Control in Nonpregnant Adults With Type 2 Diabetes. JAMA. 2018 06 19; 319(23):2430-2431.
    View in: PubMed
    Score: 0.462
  3. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med. 2018 02 06; 168(3):170-178.
    View in: PubMed
    Score: 0.446
  4. Physician perspectives on de-intensifying diabetes medications. Medicine (Baltimore). 2016 Nov; 95(46):e5388.
    View in: PubMed
    Score: 0.413
  5. Deprescribing in Older Adults With Type 2 Diabetes: Associations With Patients' Perspectives: The Diabetes and Aging Study. J Am Geriatr Soc. 2025 Apr; 73(4):1155-1167.
    View in: PubMed
    Score: 0.182
  6. Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population. Diabetes Obes Metab. 2024 Nov; 26(11):5261-5271.
    View in: PubMed
    Score: 0.178
  7. Food Insecurity and Hypoglycemia among Older Patients with Type 2 Diabetes Treated with Insulin or Sulfonylureas: The Diabetes & Aging Study. J Gen Intern Med. 2024 Oct; 39(13):2400-2406.
    View in: PubMed
    Score: 0.174
  8. Willingness to take less medication for type 2 diabetes among older patients: The Diabetes & Aging Study. J Am Geriatr Soc. 2024 Jul; 72(7):1985-1994.
    View in: PubMed
    Score: 0.172
  9. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Ann Intern Med. 2023 04; 176(4):eL230007.
    View in: PubMed
    Score: 0.161
  10. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
    View in: PubMed
    Score: 0.156
  11. The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med. 2022 02; 37(2):415-438.
    View in: PubMed
    Score: 0.144
  12. Use and Discontinuation of Insulin Treatment Among Adults Aged 75 to 79 Years With Type 2 Diabetes. JAMA Intern Med. 2019 12 01; 179(12):1633-1641.
    View in: PubMed
    Score: 0.128
  13. Guidelines on Glycemic Targets for Persons With Type 2 Diabetes-Reply. JAMA. 2018 11 13; 320(18):1937-1938.
    View in: PubMed
    Score: 0.119
  14. 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine. Diabetes Obes Metab. 2024 Feb; 26(2):463-472.
    View in: PubMed
    Score: 0.042
  15. Glycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: The Diabetes & Aging Study. J Am Geriatr Soc. 2023 12; 71(12):3692-3700.
    View in: PubMed
    Score: 0.041
  16. Patients who self-monitor blood glucose and their unused testing results. Am J Manag Care. 2015 Feb 01; 21(2):e119-29.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.